We are live on ! Find out more
MPM BioImpact

MPM BioImpact Portfolio holdings

AUM $1.64B Turnover 37.5%
1-Year Est. Return 245.64%
 

MPM BioImpact runs biotech venture, hybrid and hedge funds, and its impact funds put private and public money into companies aiming to change outcomes for patients with disease. Its hedge funds concentrate on small and mid-sized healthcare companies, while the firm as a whole combines MPM Capital's biotech venture capital record of more than 30 years with BioImpact's public investing. The firm was called MPM Oncology Impact Management until 2021 and BioImpact Capital until 2023. Ansbert Gadicke, its founder and managing partner, is also its controlling owner. Among its portfolio stories, it built the radiopharmaceutical company Aktis Oncology for solid tumors and was an early backer of argenx, an immunology company.

This Fund
S&P 500
This Quarter Est. Return
+51.43%
1 Year Est. Return
+245.64%
3 Year Est. Return
+550.3%
5 Year Est. Return
+647.56%
10 Year Est. Return
–
AUM
$282M
AUM Growth
–
Cap. Flow
+$245M
Cap. Flow %
86.79%
Top 10 Hldgs %
99.48%
Holding
12
New
12
Increased
–
Reduced
–
Closed
–
Avg Time Held
0 years
Top 10 Avg Time Held
0 years
Top 20 Avg Time Held
0 years

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 94.51%
2 Miscellaneous 5.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
HARP
1
DELISTED
Harpoon Therapeutics
HARP
$57.7M 20.43%
+389,842
New +$59.1M
2019 Q4
0 quarters
EPZM
2
DELISTED
Epizyme
EPZM
$57.4M 20.33%
+2,331,534
New +$34.6M
2019 Q4
0 quarters
TCRR
3
DELISTED
TCR2 Therapeutics
TCRR
$48.1M 17.06%
+3,370,982
New +$52.1M
2019 Q4
0 quarters
GTHX icon
4
DELISTED
G1 Therapeutics
GTHX
$37.6M 13.34%
+1,423,794
New +$33.3M
2019 Q4
0 quarters
ARQL
5
DELISTED
Arqule
ARQL
$21.8M 7.74%
+1,094,210
New +$12.7M
2019 Q4
0 quarters
DCPH icon
6
DELISTED
Deciphera Pharmaceuticals
DCPH
$13.4M 4.75%
+215,570
New +$10.2M
2019 Q4
0 quarters
ARGX icon
7
argenx
ARGX
$59.8B
$11.5M 4.08%
+71,700
New +$9.7M
2019 Q4
0 quarters
YMAB icon
8
DELISTED
Y-mAbs Therapeutics
YMAB
$10.5M 3.74%
+337,291
New +$10M
2019 Q4
0 quarters
CTMX icon
9
CytomX Therapeutics
CTMX
$434M
$7.11M 2.52%
+855,437
New +$5.77M
2019 Q4
0 quarters
VIRX icon
10
DELISTED
Viracta Therapeutics
VIRX
$949K 0.34%
+80,283
New +$1.34M
2019 Q4
0 quarters
AUTL icon
11
Autolus Therapeutics
AUTL
$309M
$525K 0.19%
+39,740
New +$520K
2019 Q4
0 quarters

Similar funds

MPM BioImpact's Q4 2019 Portfolio in Review

Q4 2019 is the first quarter with a 13F filing on record for MPM BioImpact, which disclosed 12 positions worth $282M. Its ten largest holdings account for 99% of the portfolio.

Its largest position is Harpoon Therapeutics: 389,842 shares worth $57.7M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, followed by Miscellaneous.

  • MPM BioImpact's largest Q4 2019 buy was Harpoon Therapeutics: 389,842 shares worth $57.7M.
  • MPM BioImpact's ten largest holdings make up 99% of its $282M portfolio in Q4 2019.
  • MPM BioImpact disclosed 12 positions in Q4 2019, its first 13F filing on record.

Based on MPM BioImpact's 13F filing for Q4 2019, filed 14 Feb 2020.